跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

A5159

Sigma-Aldrich

氨基蝶呤

Hybri-Max™, 50 ×, γ-irradiated, lyophilized powder, BioXtra, suitable for hybridoma

别名:

4-氨基-PGA, 4-氨基叶酸, N-[4-[[(2,4-二氨基-6-蝶啶)甲基]氨基]苯甲酰]-L-谷氨酸, （S）-2- {4 - [（2,4-二氨基胍-6-基）甲氨基]苯甲酰氨基}戊二酸

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C19H20N8O5
CAS号:
54-62-6
分子量:
440.41
Beilstein:
69045
EC 号:
200-209-9
MDL编号:
MFCD00036692
UNSPSC代码:
12352205
PubChem化学物质编号:
24890950
NACRES:
NA.75

生物来源

synthetic

质量水平

200

等级

Hybri-Max™

无菌性

γ-irradiated

产品线

BioXtra

表单

lyophilized powder

浓度

50 ×

技术

cell culture | hybridoma: suitable

杂质

endotoxin, tested

溶解性

10 mL/vial, clear, red (in TC Medium)

ε (消光系数)

24,500 at 282 nm in 0.1 M NaOH at 1 M
25,700 at 261 nm in 0.1 M NaOH at 1 M
8,100 at 373 nm in 0.1 M NaOH at 1 M

运输

dry ice

储存温度

−20°C

SMILES字符串

Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1

InChI

1S/C19H20N8O5/c20-15-14-16(27-19(21)26-15)23-8-11(24-14)7-22-10-3-1-9(2-4-10)17(30)25-12(18(31)32)5-6-13(28)29/h1-4,8,12,22H,5-7H2,(H,25,30)(H,28,29)(H,31,32)(H4,20,21,23,26,27)/t12-/m0/s1

InChI key

TVZGACDUOSZQKY-LBPRGKRZSA-N

基因信息

human ... FPGS(2356)
mouse ... Fpgs(14287)

正在寻找类似产品? 访问 产品对比指南

相关类别

应用

用于杂交瘤细胞培养应用的氨基蝶呤浓缩物添加剂。

生化/生理作用

叶酸拮抗剂。氨基蝶呤是由叶酸转运蛋白运输至细胞内的。在细胞内，它被叶酰聚谷氨酸合酶转化为一种高分子量的聚谷氨酸盐代谢物，该产物又与二氢叶酸还原酶结合并抑制其活性。氨基蝶呤-聚谷氨酸盐经 γ-谷氨酰基水解酶作用发生细胞内降解。

联系

比甲氨喋呤更有效，但毒性也更强。

重悬

10mL 无菌细胞培养基可复原一小瓶本品。储备液足以制备 500mL 培养基。最终工作浓度：0.4μM 氨基蝶呤。

法律信息

Hybri-Max is a trademark of Sigma-Aldrich Co. LLC

相关产品

产品编号
说明
价格

象形图

Skull and crossbonesHealth hazard
GHS06,GHS08

警示用语：

Danger

危险分类

Acute Tox. 1 Oral - Eye Irrit. 2 - Muta. 2 - Repr. 1B - Skin Irrit. 2

储存分类代码

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number
SLCQ7640
SLCN1310
SLCL0719
SLCD6037
SLBZ0306

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Aleem Gangjee et al.
Journal of medicinal chemistry, 48(16), 5329-5336 (2005-08-05)
We report, for the first time, the biological activities of four-carbon-atom bridged classical antifolates on dihydrofolate reductase (DHFR), thymidylate synthase (TS), and folylpolyglutamate synthetase (FPGS) as well as antitumor activity. Extension of the bridge homologation studies of classical two-carbon bridged
A Rosowsky
Current medicinal chemistry, 6(4), 329-352 (1999-04-02)
Nonpolyglutamatable antifolates are potentially of therapeutic interest for the treatment of tumors that are inherently refractory, or have become resistant, to classical antifolates as a result of decreased expression of the enzyme folylpolyglutamate synthetase. An interesting class of water-soluble nonpolyglutamatable
M Del Campo et al.
Teratology, 60(1), 10-12 (1999-07-21)
Maternal exposures to aminopterin and methotrexate have been associated with a pattern of malformation which includes prenatal-onset growth deficiency, severe lack of ossification of the calvarium, hypoplastic supraorbital ridges, small, low-set ears, micrognathia, and limb abnormalities. We report on a
Steven M Horwitz et al.
Blood, 119(18), 4115-4122 (2012-03-08)
Systemic treatment for cutaneous T-cell lymphoma (CTCL) involves the use of less aggressive, well-tolerated therapies. Pralatrexate is a novel antifolate with high affinity for reduced folate carrier-1. A dose de-escalation strategy identified recommended pralatrexate dosing for patients with CTCL that
Hatem A Azim et al.
Current opinion in oncology, 24(3), 325-331 (2012-02-22)
To discuss the clinical development of new formulations of old cytotoxic agents and highlight the value of adopting this strategy. Several drugs are currently in clinical development with high potential in improving clinical outcomes compared with their older counterparts. We
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门